Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Shanghai HeartCare Medical Technology's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 13.28%.
As of today (2026-08-29), Shanghai HeartCare Medical Technology's WACC % is 12.34%. Shanghai HeartCare Medical Technology's ROC % is 16.75% (calculated using TTM income statement data).
Shanghai HeartCare Medical Technology generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Shanghai HeartCare Medical Technology (HKSE:06609) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Shanghai HeartCare Medical Technology's WACC % is 12.34%. Shanghai HeartCare Medical Technology's ROC % is 16.75% (calculated using TTM income statement data).
Shanghai HeartCare Medical Technology generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Shanghai HeartCare Medical Technology ROC % Related Terms
Shanghai HeartCare Medical Technology ROC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai HeartCare Medical Technology (HKSE:06609) has a ROC % of 13.28% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Shanghai HeartCare Medical Technology and its competitors.
Is Shanghai HeartCare Medical Technology's ROC % too high?
Shanghai HeartCare Medical Technology's current ROC % is 13.28%. The Medical Devices & Instruments industry median ROC % is 1.73. Shanghai HeartCare Medical Technology's value of 13.28% is 667.6% above this industry median. Overall, Shanghai HeartCare Medical Technology has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai HeartCare Medical Technology's ROC % compare to ABT and SYK?
Shanghai HeartCare Medical Technology's ROC % of 13.28% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.73. Shanghai HeartCare Medical Technology's value of 13.28% is 667.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.73, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai HeartCare Medical Technology's current ROC % of 13.28% is 667.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Shanghai HeartCare Medical Technology and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai HeartCare Medical Technology's current ROC % is 13.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai HeartCare Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology (HKSE:06609) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$54.80, compared to a current price of HK$48.24 — trading 12% below its estimated fair value. The current ROC % is 13.28% and 667.6% above the Medical Devices & Instruments industry median of 1.73. Shanghai HeartCare Medical Technology's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Shanghai HeartCare Medical Technology (HKSE:06609), the current ROC % is 13.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai HeartCare Medical Technology (HKSE:06609) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology stock appears to be undervalued.
The current stock price of HK$48.24 is trading 12% below its estimated GF Value™ of HK$54.80.
GuruFocus considers Shanghai HeartCare Medical Technology to be Modestly Undervalued.
Key valuation signals for HKSE:06609:
ROC %: 13.28%
GF Value™: HK$54.80 vs. price of HK$48.24 (12% below fair value)
Industry Position: 667.6% above the Medical Devices & Instruments median
No single metric tells the full story. See the HKSE:06609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai HeartCare Medical Technology Corp Ltd is an neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. The company focuses on Research and development, manufacturing and commercialization to fulfill the unmet needs of clinicians and patients to redefine the standard of care, reduce mortality rate, and improve prognosis by continuously launching new medical devices. Geographically, the Group's majority revenue is derived from Chinese Mainland.
78GF Score
Get the complete analysis for HKSE:06609
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06609 has been successfully added to your 
